In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

Shabbir Safdar, the executive director of the Partnership for Safe Medicines, an advocacy group that tracks counterfeit drugs, said fake GLP-1 medications are “the No. 1 fraud issue” that ...

LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Kentucky leads the nation with 21 prescriptions per 1,000 residents, reflecting its 36.5% obesity rate and robust healthcare access.

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...